Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 12,500 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $34.57, for a total transaction of $432,125.00. Following the completion of the transaction, the chief executive officer now owns 441,417 shares in the company, valued at $15,259,785.69. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Cytokinetics Price Performance
Cytokinetics stock opened at $32.83 on Thursday. Cytokinetics, Incorporated has a 1-year low of $25.98 and a 1-year high of $47.49. The stock has a market cap of $3.22 billion, a PE ratio of -5.95 and a beta of 0.63. The stock’s fifty day moving average is $32.81 and its two-hundred day moving average is $34.41.
Hedge Funds Weigh In On Cytokinetics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Belpointe Asset Management LLC grew its position in shares of Cytokinetics by 76.2% in the 1st quarter. Belpointe Asset Management LLC now owns 786 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 340 shares during the last quarter. Archer Investment Corp purchased a new stake in shares of Cytokinetics in the first quarter valued at about $51,000. West Tower Group LLC acquired a new position in shares of Cytokinetics during the second quarter worth about $62,000. China Universal Asset Management Co. Ltd. raised its holdings in Cytokinetics by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,463 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 1,209 shares in the last quarter. Finally, Natixis acquired a new stake in Cytokinetics in the fourth quarter valued at about $73,000.
Analyst Ratings Changes
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
- Five stocks we like better than Cytokinetics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Is it time to buy the dip in Walmart shares?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Unlocking AI investment opportunities in healthcare
- What Are the U.K. Market Holidays? How to Invest and Trade
- New Disney investor propels stock to ranks of best S&P gainers
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.